Table 1 Clinicopathologic characteristics of patients.

From: Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients

Clinicopathologic characteristics

Responders

Non-responders

Cohort

 

Tissue (N = 5)

Blood (N = 4)

Tissue (N = 7)

Blood (N = 6)

Tissue (N = 12)

Blood (N = 10)

Age (years)

Median (range)

74 (71–81)

74.5 (71–81)

60 (43–71)

56.5 (43–71)

70.5 (43–81)

67.5 (43–81)

Sex

Male

4

3

5

5

9

8

Female

1

1

2

1

3

2

Smoking status

Smoker

2

1

4

3

6

4

Former smoker

3

3

2

2

5

5

Never smoker

0

0

1

1

1

1

Histology

Squamous

2

1

1

1

3

2

Adenocarcinoma

3

3

6

5

9

8

Stage

IIIA

0

0

1

0

1

0

IIIC

0

0

1

1

1

1

IVA

4

3

0

0

4

3

IVB

1

1

5

5

6

6

PD1/PD-L1

Positive

4

3

6

6

10

9

Negative

1

1

1

0

2

1

Response type

CR

0

0

0

0

0

0

PR

3

2

0

0

3

2

SD

2

2

0

0

2

2

PD

0

0

4

3

4

3

NE

0

0

3

3

3

3

PFS (days)

Median (range)

328 (116–952)

245 (116–952)

72 (3–148)

71 (4–148)

100 (4–952)

100 (4–952)

OS (days)

Median (range)

405 (126–952)

512 (126–952)

113 (4–364)

85.5 (4–364)

225 (4–952)

145.5 (4–952)

  1. ADC: adenocarcinoma, CR: complete response, N: number of patients, NE: non-evaluable. PD: progressive disease, PFS: progression-free survival, PR: partial response, SCC: squamous cell carcinoma, SD: stable disease, OS: overall survival.